Fundraising Fox

Eclipse Bio

San Diego, US · Founded 2017 · Delaware corporation · 42 employees on LinkedIn · 4 known investors

Find your way into Eclipse Bio

174 people in our graph share verified history with the Eclipse Bio team — schools, employers, funds. One of them is your warm intro.

Mattias Ljungmanunlockedknows Peter Chu · together at McGill University (overlapped)
×6knows the team · via McGill University
knows the team · via Eclipse Bio
×2knows the team · via Tech Coast Angels
knows the team · via University of Toronto
knows the team · via UC San Diego School of Medicine

Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Eclipse Bio was founded in 2017 by Eugene Yeo.

EYEugene Yeo
Eugene YeoFounder
PCPeter Chu
Peter ChuinCo-Founder, CEO and ChairmanPeter Chu holds a doctorate in Biomedical Sciences from UC San Diego and spent nine years as a scientist at Biogen Idec leading cancer stem cell research before founding Eclipse Therapeutics in 2011 (acquired by Bionomics in 2012), Proteona (acquired by Singleron in 2022), and co-founding Eclipse Bioinnovations in 2017 with Prof. Gene Yeo, where he serves as CEO.
EL
Eric L Van NostrandNamed on SEC filing
HK
Hallie KuhnNamed on SEC filing

Board

EWEdmond Wong
Edmond WonginBoard MemberPartner at iGlobe Partners
DV
Daniel VasellaBoard director

Investors · 4

Brainstorm VenturesSan Francisco
iGlobe PartnersSingapore · $600K – $6M
Magnetic VenturesBoston · $1M – $6M
Phoenix Venture PartnersSan Mateo · $100K – $3M

Reported raises · per SEC filings

Form D private placements

$16.9M disclosed across 2 rounds · 2021–2025

▶$4.9MraisedNov 2025 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter ChuExecutive Officer, Director
  • Daniel VasellaDirector
  • Edmond WongDirector
  • Eugene YeoDirector
Offering amount
$7.2M
Amount sold
$4.9M
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12MraisedSep 2021 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel VasellaDirector
  • Peter ChuExecutive Officer, Director
  • Eric L Van NostrandDirector
  • Hallie KuhnDirector
  • Eugene W YeoDirector
Offering amount
$15M
Amount sold
$12M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Oup78 shared keywordsOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
IDbyDNA66 shared keywordsScalable, high throughput DNA sequencing platforms.
Genewiz39 shared keywordsGENEWIZ provides sequencing, synthesis, and molecular biology services for research, clinical, and therapeutic applications, serving academic institutions, biotech companies, and pharmaceutical organizations.

Companies competing with Eclipse Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$349.8K
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$1.6M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Eclipsebio Raises $14M in Series A Financing - FinSMEsfinsmes.com · Mar 2022Biotech startup Eclipsebio emerges to shed light on RNA drug research - MedCity Newsmedcitynews.com · Mar 2022Eclipsebio Announces a $14 Million Series A Financing to Advance Its RNA Genomics Technology Platformprnewswire.com · Mar 2022

Frequently asked questions

What does Eclipse Bio do?
Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
Who founded Eclipse Bio?
Eclipse Bio was founded by Eugene Yeo in 2017.
Who are Eclipse Bio's investors?
Eclipse Bio's investors include Brainstorm Ventures, iGlobe Partners, Magnetic Ventures, Phoenix Venture Partners.
How much funding has Eclipse Bio raised?
Eclipse Bio has disclosed $16.9M raised across 2 rounds.
Where is Eclipse Bio headquartered?
Eclipse Bio is headquartered in San Diego, US.